Altered Peptide Ligand NBI-6024 Failed to Protect Insulin-Making Cells in New Type 1 Diabetes
A phase 2 trial of 188 patients found that the peptide NBI-6024, designed to stop the immune attack on insulin-producing cells, had no effect on preserving beta-cell function in newly diagnosed type 1 diabetes.
Quick Facts
What This Study Found
NBI-6024, an altered peptide ligand designed to inhibit autoreactive T-cells, failed to preserve beta-cell function in newly diagnosed type 1 diabetes patients across all three doses tested.
Mean peak C-peptide concentrations at 24 months were nearly identical across groups: 0.59 pmol/ml (0.1 mg), 0.57 pmol/ml (0.5 mg), 0.48 pmol/ml (1.0 mg), and 0.54 pmol/ml (placebo). C-peptide levels declined by approximately 60% over 24 months in all groups. Daily insulin needs at month 24 were comparable between groups. No treatment-related changes in islet antibodies or T-cell numbers were observed, suggesting the peptide failed to modulate the immune response as intended.
Key Numbers
How They Did This
This was a randomized, placebo-controlled, dose-ranging phase 2 trial. A total of 188 patients aged 10-35 with recently diagnosed type 1 diabetes were randomly assigned to receive subcutaneous injections of placebo or NBI-6024 at 0.1, 0.5, or 1.0 mg. Injections were given at baseline, weeks 2 and 4, then monthly for 24 months. Beta-cell function was measured every 3 months using C-peptide concentrations during a 2-hour mixed-meal tolerance test. Immune markers including islet antibodies and T-cell counts were also tracked.
Why This Research Matters
Type 1 diabetes affects millions worldwide, and finding a way to stop the immune system from destroying insulin-producing cells early in the disease could be transformative. While this trial was negative, it provided important data about the altered peptide ligand approach and helped guide future immune-modulation strategies for type 1 diabetes prevention.
The Bigger Picture
This negative trial is part of a broader search for immune-modulating peptides that could halt or slow type 1 diabetes progression. While NBI-6024 failed, the field has continued exploring other peptide-based immune therapies, including tolerogenic approaches and combination strategies. Negative results like these are crucial for steering research away from ineffective approaches.
What This Study Doesn't Tell Us
The study may have enrolled patients too late in the disease process for immune modulation to work, as significant beta-cell destruction may have already occurred by the time of diagnosis. The peptide may not have been potent enough to overcome the established autoimmune process. The age range of 10-35 years is broad, and younger patients may respond differently to immune modulation than adults.
Questions This Raises
- ?Would earlier intervention with immune-modulating peptides — before clinical type 1 diabetes onset — show better results?
- ?Did NBI-6024 fail because of the peptide approach itself, or because this specific peptide wasn't potent enough?
- ?Could combination therapy with other immunomodulators have enhanced NBI-6024's effect on autoreactive T-cells?
Trust & Context
- Key Stat:
- ~60% decline in beta-cell function over 24 months — identical in both treatment and placebo groups
- Evidence Grade:
- This is a well-designed randomized, placebo-controlled, dose-ranging phase 2 trial with 188 patients and 24 months of follow-up. It represents moderate-to-high quality clinical evidence, though the negative result means it demonstrates what doesn't work rather than what does.
- Study Age:
- Published in 2009, this trial informed the direction of subsequent type 1 diabetes immunotherapy research. The altered peptide ligand approach has largely been superseded by newer immune-modulation strategies, though the lessons from this trial remain relevant.
- Original Title:
- No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
- Published In:
- Diabetes care, 32(11), 2036-40 (2009)
- Database ID:
- RPEP-01562
Evidence Hierarchy
Frequently Asked Questions
What is an altered peptide ligand?
An altered peptide ligand is a modified version of a natural peptide that's been designed to change how immune cells respond. NBI-6024 was engineered to calm down the T-cells that attack insulin-producing beta cells in type 1 diabetes, but it failed to produce this effect in clinical testing.
Why are negative trial results important in peptide research?
Negative trials prevent the field from pursuing dead ends and help researchers understand which approaches don't work. This trial showed that NBI-6024 didn't modulate the immune response as hoped, helping redirect type 1 diabetes research toward other immunotherapy strategies.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01562APA
Walter, Markus; Philotheou, Areti; Bonnici, François; Ziegler, Anette-G; Jimenez, Roland. (2009). No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.. Diabetes care, 32(11), 2036-40. https://doi.org/10.2337/dc09-0449
MLA
Walter, Markus, et al. "No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.." Diabetes care, 2009. https://doi.org/10.2337/dc09-0449
RethinkPeptides
RethinkPeptides Research Database. "No effect of the altered peptide ligand NBI-6024 on beta-cel..." RPEP-01562. Retrieved from https://rethinkpeptides.com/research/walter-2009-no-effect-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.